Loading…
Tvardi Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.8% over 5Y.
today you would have $2.28▼ -99.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $4.30 | $18.36 | $26.75 | $386.64 | $438.48 | $544.68 | $579.96 | $468.00 | $440.64 | $334.44 | $606.96 | $358.92 | |
| P/E | — | — | — | — | — | — | 84.1x | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AYTUAYTU Biopharma Inc | $2.25 | — | 0.7x | — | -97.42% | $24.15M |
| DYAIDyadic International Inc | $0.61 | — | — | — | — | $24.6M |
| CLRBCellectar Biosciences, Inc. | $2.53 | — | 0.7x | — | -119.57% | $23.91M |
| NXTCNextCure, Inc. | $5.18 |
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| P/S | 37.9x | — | 3.9x | 1.9x | 13.8x | 28.3x | 5.6x | 37.9x | 38.2x | 439.2x | 2949.4x | 120.8x | 71.6x |
| P/B | 3.9x | 1.9x | — | — | 3.6x | 2.9x | 3.0x | 4.0x | 3.8x | 4.6x | 5.0x | 4.4x | 4.4x |
| EPS | -$3.26 | -$11.42 | -$78.78 | -$57.36 | -$62.64 | $6.48 | -$89.64 | -$74.16 | -$66.96 | -$75.60 | -$36.00 | -$30.60 |
| Profit margin | -549.51% | — | -411.90% | -565.21% | -204.16% | -384.06% | 6.23% | -534.91% | -549.51% | -6380.35% | -66604.65% | -649.22% | -558.55% |
| ROE | -54.61% | -86.96% | — | — | -53.83% | -38.87% | 3.38% | -56.97% | -55.39% | -66.98% | -112.92% | -23.50% | -34.35% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.7x |
| — |
| -204.56% |
| $23.71M |
| BFRIBiofrontera Inc. | $1.59 | — | 3.8x | — | -988.35% | $23.62M |
| ENLVEnlivex Ltd. | $1.35 | 0.0x | 0.0x | — | 126.17% | $23.61M |